甲磺酸阿帕替尼对晚期非小细胞肺癌CEA、CYFRA21-1、VEGF水平的影响

Effect of Apatinib mesylate on CEA,CYFRA21-1 and VEGF levels in advanced non-small cell lung cancer

目的:探讨甲磺酸阿帕替尼对晚期非小细胞肺癌血清癌胚抗原(CEA)、血管内皮生长因子(VEGF)、细胞角蛋白19片段(CYFRA21-1)水平的影响。方法:将105例经一线治疗失败后的晚期非小细胞肺癌患者随机分为两组,对照组50例予以单纯二线化疗,观察组55例在二线化疗的基础上口服甲磺酸阿帕替尼。结果:两组治疗后CEA、CYFRA21-1、VEGF水平均较治疗前降低(P<0.05),观察组低于对照组(P<0.05);观察组总有效率为92.7%,高于对照组的72.0%(P<0.05)。结论:甲磺酸阿帕替尼可有效降低血清CEA、CYFRA21-1、VEGF水平,显著提升经一线治疗无效的晚期非小细胞肺癌的临床疗效。

Objective：To investigate the effect of Apatinib mesylate on the level of serum carcinoembryonic antigen （ CEA）, vascular endothe- lial growth factor （VEGF） and cytokeratin 19 fragment （ CYFRA21 - 1 ） in patients with advanced non - small cell lung cancer. Methods ： 105 pa- tients with advanced non - small cell lung cancer who failed after first - line treatment were randomly divided into two groups. In the control group, 50 patients were given second - line chemotherapy, and 55 patients in the observation group were given Apatinib mesylate on the basis of second - line chemotherapy. Results： Alter treatment, the levels of CEA, CYFRA21 - 1 and VEGF in the two groups were significantly lower than those be- fore treatment （ P 〈 0.05）, and the observation group was significantly lower than that of the control group （ P 〈 0.05）. The total eft）ctive rate of the observation group was 92.7 %, which was significantly higher than that of the control group （72.0 % ） （ P 〈 0.05 ）. Conclusion ： Apatinib mesylate can effectively reduce the level of CEA, CYFRA21 -1 and VEGF, and can significantly improve the clinical efficacy of advanced non - small cell lung cancer which is not eft）ctive in the first line treatment.